| 9:30-10:00 | Opening (TBA) |
10:00-11:00 |
Mechanisms and Biology |
| Chairs: Moderator 1, Moderator 2,, Moderator 3 | |
| · Prostate Histology and Embriology (TBA) | |
| · Prostate cancer gene and future (TBA) | |
| · Circulating tumour cells (TBA) | |
| · What do you see under microscope and future of cooperation of pathology genetics Pathology (TBA) | |
11:00-11:15 |
Coffee Break |
11:15-12:15 |
Mechanisms & Biology & Clinic |
| Chairs: Moderator 1, Moderator 2,, Moderator 3 | |
| · Genetic base of the patient can change surgical modality” is it possible? (TBA) | |
| · New androgen receptor Blockers and future of mCRPC (TBA) | |
| · Translational medicine in prostate cancer: Urologist perspective (TBA) | |
| · Minimal invasive of Robotic Radical Prostatectomy under new anatomical points (TBA) | |
12:15-13:15 |
Lunch Buffet |
13:15-14:00 |
Clinical diagnosing |
| Chairs Moderator 1, Moderator 2,, Moderator 3 | |
| · Multiparametric MRI- should this asked less or more? (TBA) | |
| · TBA…………. (Prof Dr Pilar Laguna) | |
| · TBA…………. (Prof Dr Jean de la Rosette) | |
14:00-14:15 |
Coffee Break |
14:15-14:45 |
Case Discussion; Are The Current Criteria Enough for Active Surveillance in Prostate Cancer
|
| Chair Moderator 1, Moderator 2,, Moderator 3 | |
| Moderator: TBA
TBA, TBA, TBA, TBA |
|
14:45-15:00 |
Closing RemarksJean de la Rosette, Selcuk Guven |
Copyright 2018 | B2B Bench to Bedside - Prostate Cancer